Navigation Links
ICU Medical to Launch MicroCLAVE® Clear Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas
Date:3/31/2011

SAN CLEMENTE, Calif., March 31, 2011 /PRNewswire-FirstCall/ -- ICU Medical, Inc. (Nasdaq: ICUI) today announced that it will initiate the full market release of the MicroCLAVE Clear Neutral Displacement Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas. MicroCLAVE Clear allows clinicians to visualize the fluid path, verifying effective flushing of the patient catheter after use with blood and medications that could leave residual or fluid precipitates after aspiration or infusion. The connector's clinically proven MicroCLAVE design effectively clears blood and blood residual with flush volumes as low as 2.0 mL, while the connector's clear housing allows for visualization of the internal fluid path upon flushing the connector.

In a recent study comparing the flushing efficiency of different designs of clear needlefree connectors, the neutral displacement MicroCLAVE Clear was shown to be superior to either the positive displacement CareFusion® MaxPlus® or the negative displacement Baxter® ClearLink® as determined by the total flush volume needed to clear the connector of blood elements. The study showed that the MicroCLAVE Clear was free of blood residual after an average of 2.5mL saline flush, with 60% of the connectors flushing clear with only a 2 mL flush. By contrast, 100% of the MaxPlus connectors tested showed residual blood after a 10mL saline flush, as did 40% of the ClearLink connectors.(1)

Previous studies have demonstrated that the more proteinaceous material—including small blood clots—that resides in the connector hub, the greater the chance infection.(2) Infection is a major concern in the hospital environment and especially so given the issues of antibiotic resistance and hospital acquired infection.

Part of a full line of MicroCLAVE connectors that includes the original MicroCLAVE and the antimicrobial MicroCLAVE, MicroCLAVE Clear shares the design features that have been clinically proven to provide a safe and effective microbial barrier. The neutral displacement straight fluid path design, split-septum, and minimal deadspace of the MicroCLAVE work together to help minimize blood reflux into the tip of the catheter upon connection or disconnection of the luer. Not only does the MicroCLAVE provide enhanced patient safety through innovative technology but it has also been proven to provide an effective microbial barrier against bacteria transfer and contamination.(3-5) In addition, The MicroCLAVE's neutral displacement design may help hospitals address recent concerns raised by the FDA regarding the safety of positive displacement connectors.(6)

Media Contact: Tom McCall
Vice President, Marketing
949-366-4368
tmccall@icumed.com

(1) Sylvia, C. DVM, MS, Breznock E. DVM, PhD, Diplomate ACVS. The in vivo evaluation of the flushing efficiency of different designs of clear needlefree connectors, data on file at ICU Medical, February 2011. (2) Jarvis WR, et al Increased bloodstream infection rates in surgical patients associated with variation from recommended use and care following implementation of a needleless device. Infect Control Hosp Epidemiol. 1998 Jan; 19(1):23-7 (3) ECRI Institute, Health Devices. Evaluation of Needleless Connectors. September 2008, Volume 37, Number 9: 259-286. (4) Ryder M, RN, PhD. Bacterial transfer through needlefree connectors: Comparison of nine different devices. Poster presented at the Annual Society for Healthcare Epidemiology of America (SHEA) conference 2007, Abstract 412. (5) Moore C, RN, MBA, CIC. Maintained Low Rate of Catheter-Related Bloodstream Infections (CR-BSIs) After Discontinuation of a Luer Access Device (LAD) At an Academic Medical Center. Poster presented at the annual Association for Professionals in Infection Control and Epidemiology (APIC) Conference 2010, Abstract 4-028. (6) FDA Medical Device Safety Alert, July 28, 2010: Letter to Infection Control Practitioners Regarding Positive Displacement Needleless Connectors (http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm220459.htm).


'/>"/>
SOURCE ICU Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), a ... Uro/Gyn and Gynecology markets with innovative and proprietary products, ... March 31, 2017 after the market close on Tuesday, ... host a conference call and webcast to discuss its ... 2017 at 4:30 p.m. Eastern Time (3:30 p.m. Central ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads ... not found any of them to be very practical. She wanted to write a ... make changes in their health. It prompted her in writing “ A Clear Path ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, ... Trin, and Omega Station” is the creation of published author, Chris Jackson. Chris ... where he works in the Dallas Independent School District teaching English. He is heavily ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke ... its ANCD BRAIN device as the product advances towards regulatory and clinical phases. ...
(Date:4/22/2017)... , ... April 22, 2017 , ... Ecommerce sales have ... States estimated to be $394.9 billion. The consequences of rapid innovation and growth ... the limits of technology, it is every business and individual’s job to give something ...
(Date:4/22/2017)... ... 2017 , ... The San Juan Capistrano summer camp team at the Boys and ... for summer camps to provide physical activities for all campers. To read the report, ... , With an increase in specialty camps that focus on what the report terms as ...
Breaking Medicine News(10 mins):